**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 77450

**Manuscript Type:** SCIENTOMETRICS

**Current global research landscape on COVID-19 and cancer: Bibliometric and visualization analysis**

Zyoud S *et al*. COVID-19 and cancer

Sa'ed H Zyoud, Amer Koni, Samah W Al-Jabi, Riad Amer, Muna Shakhshir, Rand Al subu, Husam Salameh, Razan Odeh, Sultan Musleh, Faris Abushamma, Adham Abu Taha

**Sa'ed H Zyoud, Amer Koni, Samah W Al-Jabi,** Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus 44839, Palestine

**Sa'ed H Zyoud,** Clinical Research Centre, An-Najah National University Hospital, Nablus 44839, Palestine

**Amer Koni, Riad Amer, Husam Salameh, Razan Odeh, Sultan Musleh,** Hematology and Oncology Department, An-Najah National University Hospital, Nablus 44839, Palestine

**Riad Amer, Rand Al subu, Husam Salameh, Sultan Musleh, Faris Abushamma,** Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus 44839, Palestine

**Muna Shakhshir,** Department of Nutrition, An-Najah National University Hospital, Nablus 44839, Palestine

**Faris Abushamma,** Department of Urology, An-Najah National University Hospital, Nablus 44839, Palestine

**Adham Abu Taha,** Department of Pathology, An-Najah National University Hospital, Nablus 44839, Palestine

**Adham Abu Taha,** Department of Biomedical Sciences, College of Medicine and Health Sciences, An-Najah National University, Nablus 44839, Palestine

**Author contributions:** Zyoud SH designed the study, collected the data, analyzed the data, made major contributions to the manuscript’s existing literature search and interpretation, and drafted the manuscript; Koni A, Al-Jabi S, Amer R, Shakhshir M, Al subu R, Salameh H, Odeh R, Musleh S, Abushamma F, and Abu Taha A were involved in interpretation of the data, and made revisions to the initial draft; all authors provided a critical review and approved the final manuscript before submission.

**Corresponding author: Sa'ed H Zyoud, PhD, Associate Professor,** Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Academic Street, Nablus 44839, Palestine. saedzyoud@yahoo.com

**Received:** April 30, 2022

**Revised:** June 26, 2022

**Accepted:** October 11, 2022

**Published online:**

**Abstract**

BACKGROUND

Cancer is a severe public health issue that seriously jeopardizes global health. In individuals with coronavirus disease 2019 (COVID-19), cancer is considered an independent risk factor for severe illness and increased mortality.

AIM

To identify research hotspots and prospects, we used bibliometrics to examine the global production of COVID-19 literature published in the field of oncology.

METHODS

Data on publication output were identified based on the Scopus database between January 1, 2020, and June 21, 2022. This study used VOSviewer to analyze collaboration networks among countries and assess the terms most often used in the titles and abstracts of retrieved publications to determine research hotspots linked to cancer and COVID-19. The *Impact Index Per Article* for the top 10 high-cited papers collected from Reference Citation Analysis (RCA) are presented.

RESULTS

A total of 7015 publications were retrieved from the database. The United States published the greatest number of articles (2025; 28.87%), followed by Italy (964; 13.74%), the United Kingdom (839; 11.96%), and China (538; 7.67%). The *University of Texas MD Anderson Cancer Center* (*n* = 205, 2.92%) ranked first, followed by the *Memorial Sloan-Kettering Cancer Center* (*n* = 176, 2.51%).The *European Journal of Cancer* (*n* = 106, 1.51%) ranked first, followed by the *Frontiers in Oncology* (*n* = 104, 1.48%), *Cancers* (*n* = 102, 1.45%),and *Pediatric Blood and Cancer* (*n* = 95; 1.35%)*.* The hot topics were stratified into “cancer care management during the COVID-19 pandemic”; and “COVID-19 vaccines in cancer patients”.

CONCLUSION

This is the first bibliometric analysis to determine the present state and upcoming hot themes related to cancer and COVID-19 and vice versa using VOSviewer during the early stages of the pandemic. The emergence of hot themes related to cancer and COVID-19 may aid researchers in identifying new research areas in this field.

**Key Words:** Bibliometric; Scopus; COVID-19; Cancer; Coronavirus disease; VOSviewer; Reference Citation Analysis

Zyoud SH, Koni A, Al-Jabi SW, Amer R, Shakhshir M, Al subu R, Salameh H, Odeh R, Musleh S, Abushamma F, Abu Taha A. Current global research landscape on COVID-19 and cancer: Bibliometric and visualization analysis. *World J Clin Oncol* 2022; In press

**Core Tip:** Many systematic reviews and meta-analyses found that the number of papers investigating the impact of coronavirus disease 2019 (COVID-19) on cancer in various countries increased during the pandemic. The existing literature on COVID-19, focusing on cancer research, has not been provided by any bibliometric analysis. The hot topics were stratified into “cancer care management during the COVID-19 pandemic”; and “COVID-19 vaccines in cancer patients”. Cancer and COVID-19 have emerged as hot topics, which may help researchers uncover new research opportunities in this area.

**INTRODUCTION**

The first confirmed case of coronavirus disease 2019 (COVID-19) was recorded in Wuhan, China, on December 31, 2019[1]. Since that time, COVID-19 has been spreading rapidly throughout the world. Although some individuals diagnosed with COVID-19 have no symptoms, patients who become symptomatic exhibit a wide range of severity, ranging from mild respiratory symptoms to critical lung disease, sepsis, multiple organ failure, or even death[2,3]. As of June 22, 2022, a total of 538321874 cases of COVID-19 have been confirmed worldwide, including 6320599 deaths[4]. According to the Sustainable Development Goals (SDGs) Report 2020, COVID-19 halts the progress of SDG 3, which seeks to guarantee well-being and a healthy life for everyone. During the crisis, health services for cancer screening have been disrupted or ignored in many places[5].

Cancer patients represent a district group in the population with a weakened immune system due to anticancer treatments and disease activity[6,7]. In pandemics like COVID-19, cancer patients may be deprived of receiving appropriate health care as many health institutes announced shortages of their resources, along with the inadequate information available in the literature to manage them properly[8]. Therefore, health care practitioners have to decide whether to initiate or defer anticancer treatments, considering the risks and benefits of such action. Notably, patients with active cancer are highly susceptible to COVID-19. They are suspected of having serious consequences, such as admission to the intensive care unit, a requirement for mechanical ventilation, or death[9]. These unfavorable outcomes could sometimes be related to types of cancer, particularly hematologic malignancies and lung cancer[9].

Some studies reported a death rate of 28% among COVID-19 patients with cancer, which was far higher than the rate in the general population[10,11]. It was also found that certain demographics and disease-related factors, including male gender, smoking, old age, having ≥ two medical conditions, cancer status, and performance situation, were strongly associated with the mortality rate among COVID-19 cancer patients[12,13]. However, receiving antitumor therapy within four weeks of diagnosis with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was not associated with the death rate[10].

According to several systematic reviews and meta-analyses, the number of publications analyzing the impact of COVID-19 on cancer in various nations increased during the pandemic[14-18]. Although various bibliometric studies have been undertaken to evaluate COVID-19 research worldwide[19-23], limited studies have been identified that have presented the current literature on COVID-19, focusing on cancer research. The bibliometric methodology was utilized to measure and categorize research output, allowing for mapping the subject area based on the most involved authors, institutions, nations, citations, journals, and hot topics[24-28]. Therefore, this study sought to comprehensively analyze the current status of publications on COVID-19 in the oncology field through visual and bibliometric analysis. This study intends to be a valuable resource and guide for oncologists, clinicians, virologists, and epidemiologists conducting research on the emerging human coronavirus in the field of cancer in order to generate novel ideas for effective control measures and to outline COVID-19 vaccine guidance for cancer patients as soon as possible.

**MATERIALS AND METHODS**

***Data source***

The present study, which includes the analysis, was performed in June 2022. The authors utilized the Scopus database to find relevant publications as (1) it is available to the author through the “Research4 Life” library; (2) it is the largest database available, and it has a greater number of indexed journals than other databases (*e.g.*, PubMed or Web of Science) and is completely inclusive of all journals in Medline[29-31]; and (3) it indexes journals in the disciplines of health, social sciences, life sciences, and physical sciences[32,33]. In addition, Scopus has previously been used to analyze and visualize research publications on various health-related topics[34-38].

***Search strategies***

In order to obtain all publications pertaining to COVID-19 and cancer published between January 1, 2020, and June 21, 2022, we employed the ‘Advanced search’ feature of the Scopus online database. The retrieval and export of data took place within one day to avoid the risk of bias induced by ongoing database changes (June 21, 2022). The following strategy was used to retrieve data for this study (Figure 1):

**Step 1:** The phrases associated with COVID-19 were entered into the Scopus engine to accomplish the study’s objectives. They were drawn from previous bibliometric researches on COVID-19[20,21,39-41]. All selected “terms” were included in the “Article Title/Abstract/Keywords” section.

**Step 2:** The documents identified in step 1 were then limited to those having the phrases “cancer and related terms” in their titles. Cancer-related terms were taken from PubMed’s Medical Subject Headings (MeSH), and from a previous systematic and meta-analysis on COVID-19 in the oncology field[14-17,42] and placed into the Scopus engine. Some documents (*i.e.*, erratum, and retracted) were excluded (Figure 1).

***Bibliometric analysis***

The following bibliometric indicators were compiled using an Excel spreadsheet: total number of publications, type of publication, prolific countries, prolific institutions, prolific journals, and top-cited publications. Reference Citation Analysis (RCA) data were used to calculate the *Impact Index Per Article* for the top ten most cited papers. Baishideng Publishing Group Inc. owns the RCA, an open transdisciplinary citation analysis database (Pleasanton, CA 94566, United States)[43].

***Visualization analysis***

The network visualization maps were created using the VOSviewer (version 1.6.16) software program[44,45]. VOSviewer was used in our study as it is well-known as a software tool for visualizing quantitative data. VOSviewer is widely used for mapping, networking, and visualization to emphasize international collaboration and create a co-occurrence matrix to identify research hotspots based on published evidence. A node represents a certain element, such as a country or term. Stronger cooperation is shown by wider links between nodes, whereas a bigger node size suggests a large number of publications[44,45]. The study themes in the collected literature were determined by mapping the most common terms in titles/abstracts. Using VOSviewer, it is possible to create an overlay visualization in which the most recently used author terms are shown in yellow. Terms overlay visualization was based on the occurrences and average publication per year scores.

**RESULTS**

***Volume and types of publications***

At the time of data collection (June 21, 2022), Scopus has published 351577 documents on COVID-19 throughout all research fields. During the study period (January 1, 2020, to June 21, 2022), Scopus identified 7015 papers on cancer and COVID-19 which were categorized into ten types. Among them, “Article” accounted for 57.59% of the total publications (4040 articles) and was the most frequent type, followed by letters to the editor (*n* = 1061; 15.12%), and reviews (*n* = 936; 13.34%). The remaining publication types were 978 documents (13.94%).

***Contributions of countries to global publications***

We ranked ten high-output countries according to the number of publications (Table 1). The United States published the greatest number of articles (2025; 28.87%), followed by Italy (964; 13.74%), the United Kingdom (839; 11.96%), and China (538; 7.67%). Figure 2 depicts a network map of the major participating countries’ international research collaborations on cancer and COVID-19-related literature.

***Active institutions/organizations***

Table 2 shows the top ten active institutions. The *University of Texas MD Anderson Cancer Center* (*n* = 205, 2.92%) ranked first, followed by the *Memorial Sloan-Kettering Cancer Center* (*n* = 176, 2.51%) and the *Harvard Medical School* (*n* = 155; 2.21%). The majority of active institutions were from the United States (*n* = 4), followed by Italy (*n* = 3), Canada (*n* = 1), France (*n* = 1), and India (*n* = 1).

***Active journals***

For cancer and COVID-19-related literature, Table 3 shows the top ten active journals. The *European Journal of Cancer* (*n* = 106, 1.51%) ranked first, followed by the *Frontiers in Oncology* (*n* = 104, 1.48%), *Cancers* (*n* = 102, 1.45%),and *Pediatric Blood and Cancer* (*n* = 95; 1.35%)*.*

***Top cited publications***

Table 4 lists the top ten most cited works in the field of COVID-19 and cancer, ranked by total citations. The citations in the top ten ranged from 2498 to 340[9-12,46-51]. Among the top 10 papers by total citation frequency, Liang *et al*[46], published in *The Lancet Oncology* in 2020, had the greatest overall citation frequency (number of citations = 2498). The *impact index per article* of the ten most cited articles ranged from 118.5 to 1017.0 (Table 4).

***Research themes in cancer and COVID-19-related literature***

Mapping the most frequent appearing terms in the title/abstract fields of publications in cancer and COVID-19 with a minimum occurrence of 100 resulted in 253 terms being distributed into two clusters corresponding to the two primary study topics (Figure 3). The clusters are “cancer care management during the COVID-19 pandemic” (cluster 1, red), and “COVID-19 vaccines in cancer patients” (cluster 2, green); (Figure 3). The guideline, emergency, procedure, safety, process, recommendation, guidance, approach, and care are the most often used terms in cluster 2. The most often used terms in cluster 2 are vaccine, vaccination, immunotherapy, and development.

The evolution of color from dark blue to yellow represents the variation of the hot topic over time. As shown in Figure 4, researchers focused on topics related to COVID-19 vaccines in cancer patients during the last year and have become the hot research topics, attracting increasing attention.

**DISCUSSION**

This is the first bibliometric study in the field of cancer to assess and visualize COVID-19 research. We reviewed a total of 7015 publications from the Scopus database, and we present a detailed analysis of worldwide contributions and hotspots in COVID-19 and cancer research during the early stages of the pandemic. According to our study, the growing number of publications in cancer and COVID-19-related literature indicates that this topic is receiving considerable attention. During the COVID-19 pandemic, the popularity of sustainable development research has increased. The number of publications indicates that as the pandemic expanded internationally, more countries were impacted, which has led to an increase in researchers paying attention to the pandemic's influence on sustainable development[52].

One of the key hot issues in the current study was “Cancer care management during the COVID-19 pandemic”. According to several studies, the probability of developing COVID-19 in cancer patients is considered twofold higher than in the normal population. Therefore, oncologists should employ appropriate therapeutic methods in the event of a pandemic, weighing the risks of mortality from COVID-19 against the risks and benefits of continuing anticancer therapy[53-55]. Additionally, managing patients efficiently during pandemics or big crises should be a key component of the cancer care continuum. Common immunosuppressive treatments are likely to make cancer patients more vulnerable to COVID-19-related severe outcomes. Although recent studies of immunocompromised people suggest that outcomes may be less severe, several malignancy studies show a link between increased fatality rates[12,56]. These risks are likely to differ depending on the type of cancer treatmentand type of cancer[46,50,57]. According to the findings from a large systematic review and meta-analysis[58], it was shown that cancer is a comorbidity in between 1% and 2% of COVID-19 patients who are hospitalized in China, and in 5% to 7% of patients in Western nations. Based on these findings, it appears that the subjects clinically appear the same as normal individuals, and early research has shown that patients with cancer and COVID-19 have a greater in-hospital mortality risk.

Thus, this also minimizes harm in the event of a future pandemic, but it also empowers the gains generated by the current pandemic to improve overall health care delivery for all cancer patients and, by leveraging the efforts of many organizations across the cancer care stakeholders, helps all patients receive the highest-quality care while simultaneously fostering cooperation on a global scale[59,60].

Another hot subject is the COVID-19 vaccine in cancer patients. Since the early stages of the pandemic, patients with cancer have been designated as a high-risk group for COVID-19[61,62]. Therefore, the safety and effectiveness of COVID-19 vaccination in immunosuppressed persons must be better understood urgently, as excluding them and other susceptible groups from continuing trials of COVID-19 vaccines would result in inaccurate prognostic health models, which will impact subsequent pandemic waves[63,64]. Given the significant risk of morbidity and death from COVID-19 in cancer patients, current information on the safety and efficacy of the approved COVID-19 vaccinations in these patients is limited. However, the benefits likely outweigh the risks of vaccine-related adverse effects[65].

Published documents that are often cited have a large academic influence. Table 4 lists the ten cancer and COVID-19-related documents with the highest citation frequency. The most frequently cited paper on the subject is “Cancer patients with SARS-CoV-2 infection: a nationwide analysis in China,” published in *The Lancet Oncology* and cited 2498 times. This prospective observational study found that cancer patients were more likely to develop SARS-Cov-2 infection, require mechanical ventilation, and have an increased mortality risk[46]. It also showed that the clinical conditions of cancer patients got worse more rapidly than that of the other populations[46]. The paper by Zhang *et al*[47], which was published in *Annals of Oncology*, was the second most cited article. This study aimed to describe the clinical characteristics of COVID-19 patients who had cancer. The results revealed that more than 80% of patients had a dry cough, low lymphocyte count, high body temperature, low protein levels, and high value of inflammatory markers (C-reactive protein). In addition, patients who received anticancer therapy during the last two weeks were more likely to have serious consequences.

The third highest cited paper, published in *Journal of Thoracic Oncology[*49]*,* analyzed two lung cancer tissue specimens of patients with COVID-19 and showed multinucleated giant cells, exudate-containing proteins, and central reactive hyperplasia of pneumocytes, along with infiltrated patches of inflammatory cells. The paper by Kuderer *et al*[12], which was published in the *Lancet*, was the fourth most cited article. This cohort analysis of 928 cancer patients diagnosed with COVID-19 noted that male gender, smoking, old age, having ≥ two medical conditions, use of chloroquine and azithromycin, cancer status, and performance situation were the determinants of death during one month. However, the types of malignancy or antitumor treatments used did not predict the death rate.

The paper by Dai *et al*[9], which was published in *Cancer Discovery*, was the fifth most cited article. The study was carried out to compare COVID-19 cancer patients *vs* non-cancer patients and their susceptibility to COVID-19. The risk of serious outcomes, including admission to the intensive care unit, developing serious symptoms, invasive ventilation, or death, was higher in cancer patients than in non-cancer cases. Hematologic malignancies, lung cancer, and metastatic tumors were the most frequent types of cancer to have such events.

The paper by Yu *et al*[50], which was published in *JAMA Oncology*, was the sixth most cited article. According to this study, which was conducted in one center in China, the risk of contracting COVID-19 among oncology patients was found to be 0.79%. In addition, the subgroup analysis revealed a greater rate of SARS-CoV-2 infection in non-small cell lung cancer patients over 60 years old compared to those under 60 years.

The seventh most cited article was by Maringe *et al*[48] and published in the *Lancet Oncology****.*** According to this study, the COVID-19 pandemic in the UK is predicted to significantly increase the number of preventable cancer deaths in England. The COVID-19 pandemic is predicted to impact cancer patients significantly, and urgent policy initiatives are needed to address the backlog in regular diagnostic services. The paper by Lee *et al*[10], which was published in the *Lancet*, was the eighth-most cited article. The outcomes of this study revealed a high mortality rate among COVID-19 patients with active malignancy (28%). The mortality rate was significantly associated with old age, male gender, and other diseases. However, receiving anticancer treatment within four weeks of being diagnosed with SARS-CoV-2 infection was not related to the mortality rate.

The paper by Mehta *et al*[11], which was published in *Cancer Discovery*, was the ninth most cited article. This study reported a mortality rate of 28% (61/218) among COVID-19 cancer patients, which were distributed as 20 deaths of blood cancer (37%) and 41 of solid cancer (25%). The predictors of mortality were advanced age, presence of other medical conditions, a high level of inflammatory markers, and admission to the intensive care unit.

The tenth most cited article was by Feldmann *et al*[51] and published in the *Lancet*.This study revealed thattumor necrosis factor (TNF) is considered one of the main targeted therapies for certain inflammatory diseases, such as rheumatoid arthritis. Importantly, COVID-19 involves an inflammatory process with a role for TNF, indicating a possible benefit of using anti-TNF agents in COVID-19 patients. Moreover, no adverse outcome was found in COVID-19 patients who used anti-TNF therapy. Thus, there is an urgent need for clinical trials of anti-TNF treatment targeting COVID-19 patients.

***Strengths and limitations***

Publications in cancer and COVID-19-related literature were assessed and analyzed comprehensively and objectively using the largest abstract and citation database containing peer-reviewed research. Although this is the first bibliometric investigation of COVID-19 in the field of oncology, there are certain limitations: (1) The search was conducted on June 21, 2022, and included all documents from January 1, 2020, up to June 21, 2022, but the Scopus database would have been open for new documents from 2022, so this part was omitted; (2) Only publications containing the terms related to cancer in the title were retrieved; and (3) As the search was limited to Scopus indexed journals, a few publications not included in the Scopus database were missed. Other bibliometric studies have also noted some limitations[35,66,67].

**CONCLUSION**

In conclusion, this is the first bibliometric analysis to determine the present state and upcoming hot themes related to cancer and COVID-19 and vice versa using VOSviewer during the early stages of the pandemic. The top five most productive countries reporting high research on cancer and COVID-19-related literature are the United States, Italy, the United Kingdom, China, and India. In terms of publications in this discipline, the *University of Texas MD Anderson Cancer Center* and *the Memorial Sloan-Kettering Cancer Center* are the most prolific institutions. The results of the present bibliometric analysis revealed that most hot research topics have evaluated “cancer care management during the COVID-19 pandemic”, and “COVID-19 vaccines in cancer patients”. The emergence of hot themes related to cancer and COVID-19 may aid researchers in identifying new research areas in this field.

**ARTICLE HIGHLIGHTS**

***Research background***

In comparison to the general population, cancer patients with coronavirus disease 2019 (COVID-19) have a mortality rate that is two times higher.

***Research motivation***

Despite the fact that numerous bibliometric studies have been carried out to assess COVID-19 research across the globe, there are few studies that have focused on COVID-19 literature and cancer research.

***Research objectives***

Through visual and bibliometric analysis, this study aimed to thoroughly examine the current state of publications on COVID-19 in the field of cancer.

***Research methods***

The Scopus database was searched to identify publishing output data. To identify research hotspots related to cancer and COVID-19, this study used VOSviewer to analyze international collaboration networks and evaluate the terms most frequently used in the titles and abstracts of the articles retrieved. The *Impact Index Per Article* is shown for the top 10 highly cited publications gathered *via* Reference Citation Analysis (RCA).

***Research results***

The results of the present bibliometric analysis revealed that most hot research topics have evaluated “cancer care management during the COVID-19 pandemic”, and “COVID-19 vaccines in cancer patients”.

***Research conclusions***

Based on a current review of hot topics and research patterns, the findings of this study may help researchers uncover new research areas in the field of cancer and COVID-19.

***Research perspectives***

For oncologists, clinicians and virologists, this study aims to be a valuable resource and guide for research on emerging COVID-19 in the field of cancer to generate novel ideas for effective control measures and to outline COVID-19 vaccine guidance for cancer patients in the most timely manner.

**REFERENCES**

1 **Zhou P**, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; **579**: 270-273 [PMID: 32015507 DOI: 10.1038/s41586-020-2012-7]

2 **Byambasuren O,** Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv 2020: 2020.2005.2010.20097543 [DOI: 10.1101/2020.05.10.20097543]

3 **Wu Z**, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020; **323**: 1239-1242 [PMID: 32091533 DOI: 10.1001/jama.2020.2648]

4 **World Health Organisation.** WHO Coronavirus (COVID-19) Dashboard. [cited 22 June 2022]. Available from: https://covid19.who.int/

5 **The Lancet Public Health**. Will the COVID-19 pandemic threaten the SDGs? *Lancet Public Health* 2020; **5**: e460 [PMID: 32888438 DOI: 10.1016/S2468-2667(20)30189-4]

6 **Sica A**, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. *J Autoimmun* 2017; **85**: 117-125 [PMID: 28728794 DOI: 10.1016/j.jaut.2017.07.010]

7 **Battershill PM**. Influenza pandemic planning for cancer patients. *Curr Oncol* 2006; **13**: 119-120 [PMID: 17576451 DOI: 10.3390/curroncol13040012]

8 **Ueda M**, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, McCreery B, Jagels B, Crane A, Byrd DR, Pergam SA, Davidson NE, Liu C, Stewart FM. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. *J Natl Compr Canc Netw* 2020: 1-4 [PMID: 32197238 DOI: 10.6004/jnccn.2020.7560]

9 **Dai M**, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y, Xiong H, Wang C, Chen C, Xiong F, Zhang Y, Peng Y, Ge S, Zhen B, Yu T, Wang L, Wang H, Liu Y, Chen Y, Mei J, Gao X, Li Z, Gan L, He C, Li Z, Shi Y, Qi Y, Yang J, Tenen DG, Chai L, Mucci LA, Santillana M, Cai H. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. *Cancer Discov* 2020; **10**: 783-791 [PMID: 32345594 DOI: 10.1158/2159-8290.CD-20-0422]

10 **Lee LY**, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VW, Curley HM, Fittall MW, Freeman-Mills L, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJ, Lee RJ, McGrath SE, Middleton CP, Murugaesu N, Newsom-Davis T, Okines AF, Olsson-Brown AC, Palles C, Pan Y, Pettengell R, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Starkey T, Turnbull CD, Várnai C, Yousaf N; UK Coronavirus Monitoring Project Team, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet* 2020; **395**: 1919-1926 [PMID: 32473682 DOI: 10.1016/S0140-6736(20)31173-9]

11 **Mehta V**, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. *Cancer Discov* 2020; **10**: 935-941 [PMID: 32357994 DOI: 10.1158/2159-8290.CD-20-0516]

12 **Kuderer NM**, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 2020; **395**: 1907-1918 [PMID: 32473681 DOI: 10.1016/S0140-6736(20)31187-9]

13 **Yang K**, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, Lu H, Liu J, Yang J, Dong Y, Pan D, Shu C, Li J, Wei J, Huang Y, Peng L, Wu M, Zhang R, Wu B, Li Y, Cai L, Li G, Zhang T, Wu G. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. *Lancet Oncol* 2020; **21**: 904-913 [PMID: 32479787 DOI: 10.1016/S1470-2045(20)30310-7]

14 **Kaur H**, Thakur JS, Paika R, Advani SM. Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis. *Asian Pac J Cancer Prev* 2021; **22**: 1333-1349 [PMID: 34048161 DOI: 10.31557/APJCP.2021.22.5.1333]

15 **Lin Z**, Chen J, Han S. Impact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis. *Expert Rev Anticancer Ther* 2021; **21**: 1055-1066 [PMID: 33970745 DOI: 10.1080/14737140.2021.1927721]

16 **Zhang H**, Han H, He T, Labbe KE, Hernandez AV, Chen H, Velcheti V, Stebbing J, Wong KK. Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. *J Natl Cancer Inst* 2021; **113**: 371-380 [PMID: 33136163 DOI: 10.1093/jnci/djaa168]

17 **Yang L**, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. *Cancer Biol Med* 2021; **18**: 298-307 [PMID: 33628602 DOI: 10.20892/j.issn.2095-3941.2020.0559]

18 **Lei H**, Yang Y, Zhou W, Zhang M, Shen Y, Tao D, Wang L, Lei Q, Wang Y, Wu Y. Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis. *Lung Cancer* 2021; **157**: 60-65 [PMID: 33985850 DOI: 10.1016/j.lungcan.2021.05.002]

19 **Martinez-Perez C**, Alvarez-Peregrina C, Villa-Collar C, Sánchez-Tena MÁ. Citation Network Analysis of the Novel Coronavirus Disease 2019 (COVID-19). *Int J Environ Res Public Health* 2020; **17** [PMID: 33096796 DOI: 10.3390/ijerph17207690]

20 **Wang J**, Hong N. The COVID-19 research landscape: Measuring topics and collaborations using scientific literature. *Medicine (Baltimore)* 2020; **99**: e22849 [PMID: 33120818 DOI: 10.1097/MD.0000000000022849]

21 **Guleid FH**, Oyando R, Kabia E, Mumbi A, Akech S, Barasa E. A bibliometric analysis of COVID-19 research in Africa. *BMJ Glob Health* 2021; **6** [PMID: 33972261 DOI: 10.1136/bmjgh-2021-005690]

22 **Zyoud SH**, Al-Jabi SW. Mapping the situation of research on coronavirus disease-19 (COVID-19): a preliminary bibliometric analysis during the early stage of the outbreak. *BMC Infect Dis* 2020; **20**: 561 [PMID: 32738881 DOI: 10.1186/s12879-020-05293-z]

23 **Al-Jabi SW**. Current global research landscape on COVID-19 and depressive disorders: Bibliometric and visualization analysis. *World J Psychiatry* 2021; **11**: 253-264 [PMID: 34168972 DOI: 10.5498/wjp.v11.i6.253]

24 **Chahrour M**, Assi S, Bejjani M, Nasrallah AA, Salhab H, Fares M, Khachfe HH. A Bibliometric Analysis of COVID-19 Research Activity: A Call for Increased Output. *Cureus* 2020; **12**: e7357 [PMID: 32328369 DOI: 10.7759/cureus.7357]

25 **DE Felice F**, Polimeni A. Coronavirus Disease (COVID-19): A Machine Learning Bibliometric Analysis. *In Vivo* 2020; **34**: 1613-1617 [PMID: 32503819 DOI: 10.21873/invivo.11951]

26 **Gong Y**, Ma TC, Xu YY, Yang R, Gao LJ, Wu SH, Li J, Yue ML, Liang HG, He X, Yun T. Early Research on COVID-19: A Bibliometric Analysis. *Innovation (Camb)* 2020; **1**: 100027 [PMID: 32914141 DOI: 10.1016/j.xinn.2020.100027]

27 **Yu Y**, Li Y, Zhang Z, Gu Z, Zhong H, Zha Q, Yang L, Zhu C, Chen E. A bibliometric analysis using VOSviewer of publications on COVID-19. *Ann Transl Med* 2020; **8**: 816 [PMID: 32793661 DOI: 10.21037/atm-20-4235]

28 **Deng Z**, Chen J, Wang T. Bibliometric and Visualization Analysis of Human Coronaviruses: Prospects and Implications for COVID-19 Research. *Front Cell Infect Microbiol* 2020; **10**: 581404 [PMID: 33072630 DOI: 10.3389/fcimb.2020.581404]

29 **Falagas ME**, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. *FASEB J* 2008; **22**: 338-342 [PMID: 17884971 DOI: 10.1096/fj.07-9492LSF]

30 **Kokol P**, Vošner HB. Discrepancies among Scopus, Web of Science, and PubMed coverage of funding information in medical journal articles. *J Med Libr Assoc* 2018; **106**: 81-86 [PMID: 29339937 DOI: 10.5195/jmla.2018.181]

31 **Barqawi A**, Abushamma FA, Akkawi M, Al-Jabi SW, Shahwan MJ, Jairoun AA, Zyoud SH. Global trends in research related to sleeve gastrectomy: A bibliometric and visualized study. *World J Gastrointest Surg* 2021; **13**: 1509-1522 [PMID: 34950437 DOI: 10.4240/wjgs.v13.i11.1509]

32 **Harzing A-W,** Alakangas S. Google Scholar, Scopus and the Web of Science: a longitudinal and cross-disciplinary comparison. *Scientometrics* 2016; **106**: 787-804 [DOI: 10.1007/s11192-015-1798-9]

33 **Martín-Martín A,** Orduna-Malea E, Thelwall M, Delgado López-Cózar E. Google Scholar, Web of Science, and Scopus: A systematic comparison of citations in 252 subject categories. *J Informetr* 2018; **12**: 1160-1177 [DOI: 10.1016/j.joi.2018.09.002]

34 **Şahin S**, Sivri N, Akpinar I, Çinçin ZB, Sönmez VZ. A comprehensive bibliometric overview: antibiotic resistance and Escherichia coli in natural water. *Environ Sci Pollut Res Int* 2021 [PMID: 33959839 DOI: 10.1007/s11356-021-14084-1]

35 **Zyoud SH**, Smale S, Waring WS, Sweileh W, Al-Jabi SW. Global research trends in the microbiome related to irritable bowel syndrome: A bibliometric and visualized study. *World J Gastroenterol* 2021; **27**: 1341-1353 [PMID: 33833487 DOI: 10.3748/wjg.v27.i13.1341]

36 **Li N**, Wang L, Hu Y, Han W, Zheng F, Song W, Jiang J. Global evolution of research on pulmonary nodules: a bibliometric analysis. *Future Oncol* 2021; **17**: 2631-2645 [PMID: 33880950 DOI: 10.2217/fon-2020-0987]

37 **Sweileh WM**. Global research activity on antimicrobial resistance in food-producing animals. *Arch Public Health* 2021; **79**: 49 [PMID: 33849636 DOI: 10.1186/s13690-021-00572-w]

38 **Zyoud SH**. The Arab region's contribution to global COVID-19 research: Bibliometric and visualization analysis. *Global Health* 2021; **17**: 31 [PMID: 33766073 DOI: 10.1186/s12992-021-00690-8]

39 **Aristovnik A,** Ravšelj D, Umek L. A Bibliometric Analysis of COVID-19 across Science and Social Science Research Landscape. *Sustainability* 2020; **12**: 9132 [DOI: 10.3390/su12219132]

40 **Furstenau LB**, Rabaioli B, Sott MK, Cossul D, Bender MS, Farina EMJM, Filho FNB, Severo PP, Dohan MS, Bragazzi NL. A Bibliometric Network Analysis of Coronavirus during the First Eight Months of COVID-19 in 2020. *Int J Environ Res Public Health* 2021; **18** [PMID: 33499127 DOI: 10.3390/ijerph18030952]

41 **Cernile G**, Heritage T, Sebire NJ, Gordon B, Schwering T, Kazemlou S, Borecki Y. Network graph representation of COVID-19 scientific publications to aid knowledge discovery. *BMJ Health Care Inform* 2021; **28** [PMID: 33419870 DOI: 10.1136/bmjhci-2020-100254]

42 **Saleh G**, Ahmed A, Hassanain O, Emad A, Essameldin S, Ragai M, Saad Y. Nutrition in Cancer Patients Positive for COVID-19; Case Series and a Systematic Review of Literature. *Nutr Cancer* 2022; **74**: 450-462 [PMID: 34080508 DOI: 10.1080/01635581.2021.1931363]

43 **Baishideng Publishing Group Inc.** Reference Citation Analysis. 2022. [cited 23 June 2022]. Available from: https://www.referencecitationanalysis.com/

44 **van Eck NJ**, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. *Scientometrics* 2010; **84**: 523-538 [PMID: 20585380 DOI: 10.1007/s11192-009-0146-3]

45 **van Eck NJ**, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. *Scientometrics* 2017; **111**: 1053-1070 [PMID: 28490825 DOI: 10.1007/s11192-017-2300-7]

46 **Liang W**, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020; **21**: 335-337 [PMID: 32066541 DOI: 10.1016/S1470-2045(20)30096-6]

47 **Zhang L**, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Ann Oncol* 2020; **31**: 894-901 [PMID: 32224151 DOI: 10.1016/j.annonc.2020.03.296]

48 **Maringe C**, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, Rachet B, Aggarwal A. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol* 2020; **21**: 1023-1034 [PMID: 32702310 DOI: 10.1016/S1470-2045(20)30388-0]

49 **Tian S**, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. *J Thorac Oncol* 2020; **15**: 700-704 [PMID: 32114094 DOI: 10.1016/j.jtho.2020.02.010]

50 **Yu J**, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. *JAMA Oncol* 2020; **6**: 1108-1110 [PMID: 32211820 DOI: 10.1001/jamaoncol.2020.0980]

51 **Feldmann M**, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, Richards D, Hussell T. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. *Lancet* 2020; **395**: 1407-1409 [PMID: 32278362 DOI: 10.1016/S0140-6736(20)30858-8]

52 **Wang Q**, Huang R. The impact of COVID-19 pandemic on sustainable development goals - A survey. *Environ Res* 2021; **202**: 111637 [PMID: 34233155 DOI: 10.1016/j.envres.2021.111637]

53 **Al-Shamsi HO**, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. *Oncologist* 2020; **25**: e936-e945 [PMID: 32243668 DOI: 10.1634/theoncologist.2020-0213]

54 **Hanna TP**, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. *Nat Rev Clin Oncol* 2020; **17**: 268-270 [PMID: 32242095 DOI: 10.1038/s41571-020-0362-6]

55 **Jafari A**, Rezaei-Tavirani M, Karami S, Yazdani M, Zali H, Jafari Z. Cancer Care Management During the COVID-19 Pandemic. *Risk Manag Healthc Policy* 2020; **13**: 1711-1721 [PMID: 33061705 DOI: 10.2147/RMHP.S261357]

56 **UK Coronavirus Cancer Monitoring Project team**. The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19. *Lancet Oncol* 2020; **21**: 622-624 [PMID: 32304634 DOI: 10.1016/S1470-2045(20)30230-8]

57 **Wu C**, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020; **180**: 934-943 [PMID: 32167524 DOI: 10.1001/jamainternmed.2020.0994]

58 **Zarifkar P**, Kamath A, Robinson C, Morgulchik N, Shah SFH, Cheng TKM, Dominic C, Fehintola AO, Bhalla G, Ahillan T, Mourgue d'Algue L, Lee J, Pareek A, Carey M, Hughes DJ, Miller M, Woodcock VK, Shrotri M. Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis. *Clin Oncol (R Coll Radiol)* 2021; **33**: e180-e191 [PMID: 33261978 DOI: 10.1016/j.clon.2020.11.006]

59 **Jazieh AR**, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, Mula-Hussain L, Errihani H, Khattak A, De Guzman RB, Mathias C, Alkaiyat MOF, Jradi H, Rolfo C; International Research Network on COVID-19 Impact on Cancer Care. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. *JCO Glob Oncol* 2020; **6**: 1428-1438 [PMID: 32986516 DOI: 10.1200/GO.20.00351]

60 **Qian X**, Ren R, Wang Y, Guo Y, Fang J, Wu ZD, Liu PL, Han TR; Members of Steering Committee, Society of Global Health, Chinese Preventive Medicine Association. Fighting against the common enemy of COVID-19: a practice of building a community with a shared future for mankind. *Infect Dis Poverty* 2020; **9**: 34 [PMID: 32264957 DOI: 10.1186/s40249-020-00650-1]

61 **The Lancet Oncology**. COVID-19 and cancer: 1 year on. *Lancet Oncol* 2021; **22**: 411 [PMID: 33794199 DOI: 10.1016/S1470-2045(21)00148-0]

62 **Korompoki E**, Gavriatopoulou M, Kontoyiannis DP. COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization. *JAMA Oncol* 2021; **7**: 1113-1114 [PMID: 33983372 DOI: 10.1001/jamaoncol.2021.1218]

63 **Gnanvi JE**, Salako KV, Kotanmi GB, Glèlè Kakaï R. On the reliability of predictions on Covid-19 dynamics: A systematic and critical review of modelling techniques. *Infect Dis Model* 2021; **6**: 258-272 [PMID: 33458453 DOI: 10.1016/j.idm.2020.12.008]

64 **Trapani D**, Curigliano G. COVID-19 vaccines in patients with cancer. *Lancet Oncol* 2021; **22**: 738-739 [PMID: 34087120 DOI: 10.1016/S1470-2045(21)00250-3]

65 **Desai A**, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol* 2021; **18**: 313-319 [PMID: 33723371 DOI: 10.1038/s41571-021-00487-z]

66 **Zyoud SH**, Smale S, Waring WS, Sweileh WM, Al-Jabi SW. Global research trends in microbiome-gut-brain axis during 2009-2018: a bibliometric and visualized study. *BMC Gastroenterol* 2019; **19**: 158 [PMID: 31470803 DOI: 10.1186/s12876-019-1076-z]

67 **Al-Jabi SW**. Arab world's growing contribution to global leishmaniasis research (1998-2017): a bibliometric study. *BMC Public Health* 2019; **19**: 625 [PMID: 31118003 DOI: 10.1186/s12889-019-6969-9]

**Footnotes**

**Conflict-of-interest statement:** All authors report no relevant conflict of interest for this article.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 30, 2022

**First decision:** June 8, 2022

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Palestine

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Ke L, China; Preziosi F, Italy **S-Editor:** Wu YXJ **L-Editor:** Webster JR **P-Editor:**

**Figure Legends**



**Figure 1 Flowchart for including and excluding literature studies.**

****

**Figure 2 International collaboration in cancer and coronavirus disease 2019-related literature is visualized as a network map among the most active countries.** This graphical collaboration map was created after a minimum of 50 publications were placed in each country. Of 143 countries working in this field, 33 met this threshold. The node size denotes the number of publications for that country.

****

**Figure 3 Map of terms in the title/abstract fields of papers relating to cancer and coronavirus disease 2019 as a network visualization.** This graphical map of terms was created by placing the minimum number of term occurrences at least 100 times. Out of 75191 terms in this field, 253 terms met this criterion, grouped into three clusters and colored differently. The node size denotes the number of articles that contain that term.

****

**Figure 4 Overlay visualization of terms co-occurrence cluster analysis.** The color of the nodes, which denotes the average publication year, changes from dark blue to yellow, representing the average publication year of the keyword from 2000 to 2022.

**Table 1 Publication contributions of the top 10 productive countries**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ranking** | **Country** | **Number of documents** | **%** |
| 1st | United States | 2025 | 28.87 |
| 2nd | Italy | 964 | 13.74 |
| 3rd | United Kingdom | 839 | 11.96 |
| 4th | China | 538 | 7.67 |
| 5th | India | 489 | 6.97 |
| 6th | France | 403 | 5.74 |
| 7th | Canada | 363 | 5.17 |
| 8th | Germany | 349 | 4.98 |
| 9th | Spain | 327 | 4.66 |
| 10th | Australia | 237 | 3.38 |

**Table 2 Top ten active institutions/organizations on research related to coronavirus disease 2019 and cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ranking** | **Institution** | **Country** | ***n*** | **%** |
| 1st | University of Texas MD Anderson Cancer Center | USA | 205 | 2.92 |
| 2nd | Memorial Sloan-Kettering Cancer Center | USA | 176 | 2.51 |
| 3rd | Harvard Medical School | USA | 155 | 2.21 |
| 4th | Dana-Farber Cancer Institute | USA | 152 | 2.17 |
| 5th | University of Toronto | Canada | 132 | 1.88 |
| 5th | Università degli Studi di Milano | Italy | 127 | 1.81 |
| 7th | Istituto Europeo di Oncologia | Italy | 121 | 1.72 |
| 8th | INSERM | France | 120 | 1.71 |
| 9th | Fondazione IRCCS Istituto Nazionale dei Tumori, Milan | Italy | 119 | 1.70 |
| 10th | Tata Memorial Hospital | India | 116 | 1.65 |

**Table 3 Top ten active journals on research related to coronavirus disease 2019 and cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ranking** | **Journal** | ***n*** | **%** | **IF** |
| 1st | European Journal of Cancer | 106 | 1.51 | 9.162 |
| 2nd | Frontiers in Oncology | 104 | 1.48 | 6.244 |
| 2nd | Cancers | 102 | 1.45 | 6.639 |
| 4th | Pediatric Blood and Cancer | 95 | 1.35 | 3.167 |
| 5th | Lancet Oncology | 90 | 1.28 | 41.316 |
| 6th | Supportive Care in Cancer | 86 | 1.23 | 3.603 |
| 7th | Cancer | 81 | 1.15 | 6.860 |
| 8th | JAMA Oncology | 75 | 1.07 | 31.777 |
| 9th | JCO Oncology Practice | 73 | 1.04 | NA |
| 10th | Advances in Radiation Oncology | 60 | 0.86 | NA |

IF is the impact factor for 2020 journals listed in Clarivate Analytics, Incites Journal Citation Reports.

**Table 4 List of the top 10 cited articles for coronavirus disease 2019 studies related to cancer between January 1, 2020, and June 21, 2022**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ranking** | **Authors** | **Title** | **Year** | **Source title** | **Cited by** | **Impact Index Per Article1** |
| 1st | Liang *et al*[46] | “Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China” | 2020 | The Lancet Oncology | 2498 | 1017.0 |
| 2nd | Zhang *et al*[47] | “Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China” | 2020 | Annals of Oncology | 859 | 296.0 |
| 3rd | Tian *et al*[49] | “Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer” | 2020 | Journal of Thoracic Oncology | 835 | 315.5 |
| 4th | Kuderer *et al*[12] | “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study” | 2020 | The Lancet | 825 | 292.5 |
| 5th | Dai *et al*[9] | “Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak | 2020 | Cancer Discovery | 774 | 118.5 |
| 6th | Yu *et al*[50] | SARS-CoV-2” “Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan, China” | 2020 | JAMA Oncology | 659 | 236.0 |
| 7th | Maringe *et al*[48] | “The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study” | 2020 | The Lancet Oncology | 579 | 189.0 |
| 8th | Lee *et al*[10] | “COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study” | 2020 | The Lancet | 574 | 210.5 |
| 9th | Mehta *et al*[11] | “Case fatality rate of cancer patients with COVID-19 in a New York Hospital system” | 2020 | Cancer Discovery | 426 | 158.5 |
| 10th | Feldmann *et al*[51] | “Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed” | 2020 | The Lancet | 340 | 140.0 |

1The Impact Index Per Article is presented based on Reference Citation Analysis.